Get the latest Science News and Discoveries

AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal ... - EurekAlert

Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center. The findings were presented today in a plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2024 by Scott Kopetz, M.D., Ph.D., professor of Gastrointestinal Medical Oncology and associate vice president of Translational Integration, and published in Cancer Discovery, a journal of the AACR.

None

Get the Android app

Or read this on Eureka Alert